Adjuvant Study of high-risk Muscle Invasive Urothelial Carcinoma Open-label, multicenter, randomized Phase III Study with Atezolizumab (Anti-PD-L1 Antibody) as adjuvant Therapy compared with Observation in Patients with high-risk Muscle Invasive Urothelial Carcinoma after Surgical Resection (IMvigor010) Study AB 53/15 of the AUO

被引：0
|
作者：
Rexer, H. [1 ]
Retz, M. [2 ]
Albers, P. [3 ]
机构：
[1] MeckEvidence, AUO Geschaftsstelle, Seestr 11, D-17252 Schwarz, Germany
[2] Tech Univ Munich, Klinikum Rechts Isar, Urol Klin & Poliklin, Munich, Germany
[3] Univ Klinikum Dusseldorf, Urol Klin, Dusseldorf, Germany
来源：
UROLOGE | 2016年 / 55卷 / 11期
关键词：
D O I：
10.1007/s00120-016-0248-5
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1491 / 1493
页数：3
相关论文
共 50 条
  • [1] IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).
    Hussain, Maha H. A.
    Powles, Thomas
    Albers, Peter
    Castellano, Daniel
    Daneshmand, Siamak
    Gschwend, Juergen
    Nishiyama, Hiroyuki
    Oudard, Stephane
    Tayama, Darren
    Davarpanah, Nicole N.
    Degaonkar, Viraj
    Shi, Yi
    Mariathasan, Sanjeev
    Grivas, Petros
    Peter, H. O.
    Rosenberg, Jonathan E.
    Geynisman, Daniel M.
    Hoffman-Censits, Jean H.
    Peter Petrylak, Daniel
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
    Bellmunt, Joaquim
    Hussain, Maha
    Gschwend, Jurgen E.
    Albers, Peter
    Oudard, Stephane
    Castellano, Daniel
    Daneshmand, Siamak
    Nishiyama, Hiroyuki
    Majchrowicz, Martin
    Degaonkar, Viraj
    Shi, Yi
    Mariathasan, Sanjeev
    Grivas, Petros
    Drakaki, Alexandra
    O'Donnell, Peter H.
    Rosenberg, Jonathan E.
    Geynisman, Daniel M.
    Petrylak, Daniel P.
    Hoffman-Censits, Jean
    Bedke, Jens
    Kalebasty, Arash Rezazadeh
    Zakharia, Yousef
    van der Heijden, Michiel S.
    Sternberg, Cora N.
    Davarpanah, Nicole N.
    Powles, Thomas
    LANCET ONCOLOGY, 2021, 22 (04) : 525 - 537
  • [3] Adjuvante Studie beim muskelinvasiven Hoch-Risiko-UrothelkarzinomEine offene, multizentrische, randomisierte Phase-III-Studie mit Atezolizumab (Anti-PD-L1-Antikörper) als adjuvante Therapie im Vergleich mit einer Beobachtung bei Patienten mit muskelinvasivem Hoch-Risiko-Urothelkarzinom nach operativer Entfernung (IMvigor010) – Studie AB 53/15 der AUOAdjuvant study of high-risk muscle invasive urothelial carcinomaOpen-label, multicenter, randomized phase III study with atezolizumab (anti-PD-L1 antibody) as adjuvant therapy compared with observation in patients with high-risk muscle invasive urothelial carcinoma after surgical resection (IMvigor010)— study AB 53/15 of the AUO
    H. Rexer
    M. Retz
    P. Albers
    Der Urologe, 2016, 55 (11): : 1491 - 1493
  • [4] Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison
    Chen, Wei
    Yoshida, Soichiro
    Miura, Noriyoshi
    Fukuda, Shohei
    Fukushima, Hiroshi
    Waseda, Yuma
    Tanaka, Hajime
    Fujii, Yasuhisa
    FRONTIERS IN ONCOLOGY, 2025, 14
  • [5] A Phase III, randomized, double-blind, multicenter study of adjuvant nivolumab vs placebo in patients (pts) with high-risk invasive urothelial carcinoma (UC; CheckMate 274)
    Bajorin, D.
    Galsky, M. D.
    Gschwend, J. E.
    Tomita, Y.
    Azrilevich, A.
    Witjes, F.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] First-line Treatment for locally advanced or metastatic Urothelial Carcinoma: A randomized, double-blind Phase-III-Multicenter Study of adjuvant Nivolumab Therapy versus Placebo in Patients with invasive High-Risk Urothelial Carcinoma
    Rexer, H.
    Ohlmann, C. -H.
    Gschwend, J.
    AKTUELLE UROLOGIE, 2018, 49 (04) : 308 - 309
  • [7] Adjuvant Therapy of Renal Cell Carcinoma with high Risk of Recurrence after Nephrectomy A randomized, multicentre, Placebo-controlled, double-blind Phase III Study of Atezolizumab (Anti-PD-L1 Antibody) as adjuvant Therapy for Patients with Renal Cell Carcinoma and a high Recurrence Risk after Nephrectomy (IMmotion010) - AN 42/16 of AUO
    Rexer, H.
    Doehn, C.
    Gruellich, C.
    UROLOGE, 2018, 57 (05): : 643 - 644
  • [8] First line therapy for locally advanced or metastatic urothelial cancer: A randomized double blind phase III multicenter study on adjuvant nivolumab therapy versus placebo in patients with invasive high-risk urothelial cancer (CheckMate 274)—AB 58/17 of the AUO
    Rexer H.
    Ohlmann C.-H.
    Gschwend J.
    Der Urologe, 2017, 56 (10): : 1331 - 1332
  • [9] Efficacy and safety of adjuvant therapy with nivolumab or placebo in high-risk patients with muscle-invasive urothelial carcinoma after radical surgery: review of the first results of the randomized phase III trial CheckMate 274
    Volkova, M., I
    Olshanskaya, A. S.
    Kalinin, S. A.
    ONKOUROLOGIYA, 2021, 17 (01): : 108 - 119
  • [10] Clinical Effectiveness of Tislelizumab With Gemcitabine/Cisplatin Versus Gemcitabine/Cisplatin Alone as Adjuvant Therapy for High-Risk Muscle-Invasive Urothelial Carcinoma: A Real-World Study
    Wang, Yanjun
    Zhong, Kaihua
    Tan, Xingliang
    Zhou, Qianghua
    Jiang, Lijuan
    Yao, Kai
    Wu, Zhiming
    CANCER MEDICINE, 2025, 14 (04):
12345